A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
This multi-center, randomized, double-blind, active controlled, parallel-group study in type
2 diabetes patients with moderate renal impairment will evaluate the effect on renal function
and the safety and tolerability of aleglitazar compared with pioglitazone. Patients will be
randomized to receive either 150 mcg aleglitazar or 45 mg pioglitazone as daily oral doses.
In addition, a diet and exercise plan will also be implemented during the anticipated time on
study treatment of 52 weeks. The target sample size is 200-400 patients.